ORAL BIOLIFE AWARDED NIH GRANT TO ADVANCE PIEZOELECTRIC REGENERATIVE PLATFORM FOR PERI-IMPLANTITIS

NIH-funded research expands evaluation of Oral Biolife's technology into a significant new indication involving bone loss around dental implants

BETHLEHEM, PA, UNITED STATES, September 10, 2026 / EINPresswire.com/ -- Oral Biolife (OBL), a biotechnology company developing a first-in-class piezoelectric regenerative platform designed to stimulate new bone formation, today announced that it has been awarded a grant from the National Institutes of Health (NIH), through the National Institute of Dental and Craniofacial Research (NIDCR), to investigate its technology as a potential non-surgical treatment approach for peri-implantitis.

The NIH award represents an important external validation of Oral Biolife's expanding regenerative platform and supports the evaluation of its technology beyond periodontal bone regeneration into an additional dental indication characterized by progressive bone loss.

Peri-implantitis is an inflammatory condition affecting the tissues surrounding dental implants that can result in progressive loss of supporting bone and, ultimately, implant failure. Current treatment can require surgical intervention, creating a significant need for effective approaches capable of addressing both the disease and associated bone loss with less invasive treatment.

The study will be led by Ronaldo Santana, DMD, Professor and Chair of the Department of Periodontology and Oral Implantology at Temple University's Maurice H. Kornberg School of Dentistry, who will serve as Principal Investigator.

"Dr. Santana brings exceptional scientific and clinical expertise in periodontology, implantology and regenerative dentistry to this program," said Bill Breitenbach, Chief Strategy and Innovation Officer of Oral Biolife. "Having an investigator of his caliber lead this NIH-supported research is important as we rigorously evaluate the potential of our technology in peri-implantitis and continue building the scientific evidence supporting the broader Oral Biolife platform."

Oral Biolife's lead human product, Ambrilux™ Dental Gel, is in development for periodontal bone regeneration. The company's proprietary piezoelectric platform is designed to convert naturally occurring mechanical forces into localized bioelectric signals that stimulate physiological pathways associated with bone formation.

The NIH-funded peri-implantitis program provides an opportunity to evaluate whether this regenerative mechanism can address another important area of unmet need in dentistry and further demonstrate the potential applicability of Oral Biolife's technology across multiple bone-regeneration indications.

"This award is an important milestone for Oral Biolife and a testament to the extraordinary work of our scientific, clinical and development teams," said Dr. Stella Vnook, President and CEO of Oral Biolife. "We are grateful for NIH's support and for Dr. Santana's leadership of this program. Most importantly, this research brings us another step closer to our goal of developing regenerative treatments that can meaningfully change how patients with bone loss are treated. I am incredibly excited about what is ahead for Oral Biolife, our platform and the patients we ultimately hope to serve."

The award further advances Oral Biolife's strategy of establishing its piezoelectric technology as a regenerative platform with potential applications beyond its initial periodontal indication. Future development opportunities include additional dental and craniofacial applications as well as orthopedic indications involving bone regeneration.

About Oral Biolife Inc.
Oral Biolife is building the mechanical foundation for the next generation of regenerative medicine. The company's piezoelectric regenerative platform converts endogenous mechanical forces into localized bioelectric signaling that activates physiological bone formation. Oral Biolife's lead human product, Ambrilux™ Dental Gel, is in clinical development for periodontal bone regeneration. The company's veterinary product, Restoris™, launched in 2025.

Emily Thomas
Kafka Media Group
email us here
+1 407-603-5716

This press release can be viewed online at: https://www.einpresswire.com/article/941195294

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.